-
Hot Stock List: ImmunoCellular Therapeutics, (NYSEMKT:IMUC), Verizon Communications Inc. (NYSE:VZ), Zhaopin (NYSE:ZPIN), Medtronic plc (NYSE:MDT), Calix Inc. (NYSE:CALX)
On Friday shares of ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) closed at $0.48. On May 11, ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) announced financial results for the first quarter 2015. For the quarter ended March 31, 2015, the Company reported a net loss of $1.4 million, or $0.02 per basic and diluted share, compared to a net loss of…
-
Active Movers: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), First Solar (NASDAQ:FSLR), PrivateBancorp (NASDAQ:PVTB), Invesco (NYSE:IVZ), Zhaopin (NYSE:ZPIN)
Valeant Pharmaceuticals International Inc. (NYSE:VRX) has agreed to buy Salix Pharmaceuticals Ltd. for about $10 billion in cash. The companies said Sunday that their boards of directors approved the transaction, which amounts to about $158 for each of Salix’s outstanding shares—just above the Raleigh, North Carolina-based Salix’s closing price of $157.85 per share on Friday.…
-
Trader’s Alert: Ascendis Pharma A/S (NASDAQ:ASND), Travelzoo Inc. (NASDAQ:TZOO), Ford Motor Company (NYSE:F), Armstrong World Industries (NYSE:AWI), Zhaopin (NYSE:ZPIN)
Wells Fargo & Co. started coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note released on Monday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. On Monday shares of Ascendis Pharma A/S (NASDAQ:ASND) closed at $18.20. On February 17, Travelzoo Inc. (NASDAQ:TZOO) announced the winners of the 2014…
-
Market Wrap Up: Chevron Corporation (NYSE:CVX), Rosetta Resources (NASDAQ:ROSE), Cliffs Natural Resources Inc. (NYSE:CLF), Zhaopin (NYSE:ZPIN), DRDGOLD (NYSE:DRD)
Chevron said on Jan 30, that it would abandon efforts to find and produce natural gas from shale rock in Poland, in perhaps the biggest setback yet to fledgling efforts to start a European shale oil and gas industry that might help replace the region’s dwindling fuel resources. On Monday shares of Chevron Corporation (NYSE:CVX)…
-
Traders Are Gambling on: Halozyme Therapeutics (NASDAQ:HALO), Groupon (NASDAQ:GRPN), Zhaopin (NYSE:ZPIN), Sun Bancorp Inc. (NASDAQ:SNBC), Alcatel Lucent (NYSE:ALU)
On 21 January, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has 0.70% insider ownership while its institutional ownership stands at 71.60%. In last trading activity company’s stock closed at $14.28. On 28 January,…
-
Don’t Miss These Stocks: Five Below (NASDAQ:FIVE), ARRIS Group (NASDAQ:ARRS), Zhaopin (NYSE:ZPIN), Morgans Hotel (NASDAQ:MHGC), WGL Holdings Inc. (NYSE:WGL)
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 10, 2015 to file lead plaintiff applications in a securities class action lawsuit against Five Below, Inc. (NASDAQ:FIVE) if they purchased the Company’s securities between June 5, 2014 and…
-
Investors Are Eying: Zhaopin (NYSE:ZPIN), Transocean (NYSE:RIG), Goodrich Petroleum Corp. (NYSE:GDP), Eagle Rock Energy Partners, L.P. (NASDAQ:EROC), Tiptree Financial (NASDAQ:TIPT)
Evan Guo, chief executive officer of Zhaopin Ltd. (NYSE:ZPIN), said the Internet finance talent pool comprises professionals from banks, insurance and technology companies. He said that he has been receiving complaints from insurance companies lately about their core t staff being aggressively approached by the fast－growing Internet finance companies. Zhaopin Ltd. (NYSE:ZPIN) in last trading…
-
Investor’s Choice: JUNO THERAPEUTICS (NASDAQ:JUNO), AK Steel Holding Corporation (NYSE:AKS), Atlantic Tele-Network (NASDAQ:ATNI), Zhaopin (NYSE:ZPIN), Johnson & Johnson (NYSE:JNJ)
In 2015, Seattle’s rising star biotech company JUNO THERAPEUTICS, INC. (NASDAQ:JUNO) will have to put its money where its mouth is in terms of developing scalable, commercial cancer treatments. Juno made waves in 2014 as it raisedmassive amounts of venture capital funding , produced promising clinical trial results boasting up to 91 percent cancer cure…